The estimated Net Worth of David Cavalier is at least $6.18 ezer dollars as of 29 April 2019. Mr. Cavalier owns over 2,000 units of Anixa Biosciences stock worth over $6,180 and over the last 6 years he sold ANIX stock worth over $0. In addition, he makes $0 as Independent Director at Anixa Biosciences.
Sign up
Mr. Cavalier ANIX stock SEC Form 4 insiders trading
David has made over 1 trades of the Anixa Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of ANIX stock worth $8,420 on 29 April 2019.
The largest trade he's ever made was buying 2,000 units of Anixa Biosciences stock on 29 April 2019 worth over $8,420. On average, David trades about 500 units every 0 days since 2018. As of 29 April 2019 he still owns at least 2,000 units of Anixa Biosciences stock.
You can see the complete history of Mr. Cavalier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Cavalier biography
David C. Cavalier serves as Independent Director of the Company. He is currently the Chief Operating Officer of Mab & Stoke, Inc., a direct-to-consumer health and wellness company. He was the Chairman, from 2004 to 2018, and Chief Financial Officer, from 2013 to 2018, of Aeolus Pharmaceuticals, Inc., a biotechnology company where in 2011 he was instrumental in winning and managing a $118 million advanced research and development contract from the U.S. Government. Prior to Aeolus, Mr. Cavalier was the founder, portfolio manager and Chief Operating Officer of Xmark Opportunity Partners, a biotechnology investment firm. Xmark was an activist fund, focused on creating positive change at the board and management level for portfolio companies. He began his biotech investment career at Brown Simpson Asset Management, where he co-managed the life sciences investment group. Mr. Cavalier previously worked for Tiger Real Estate, a private investment fund sponsored by Tiger Management Corporation. He began his career in the Investment Banking Division of Goldman, Sachs & Co. working on debt and equity offerings for public and private real estate companies. Mr. Cavalier currently serves as the Chairman of the New York Advisory Board for Enterprise Community Partners, a non-profit focused on policy, program and capital solutions for affordable housing. He received his B.A. from Yale University and his M.Phil. from Oxford University.
How old is David Cavalier?
David Cavalier is 50, he's been the Independent Director of Anixa Biosciences since 2018. There are 10 older and no younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
What's David Cavalier's mailing address?
David's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118.
Insiders trading at Anixa Biosciences
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton és Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
What does Anixa Biosciences do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
What does Anixa Biosciences's logo look like?
Complete history of Mr. Cavalier stock trades at Anixa Biosciences
Anixa Biosciences executives and stock owners
Anixa Biosciences executives and other stock owners filed with the SEC include:
-
Dr. Amit Kumar Ph.D.,
Chairman, Pres & CEO -
Amit Kumar,
Chairman of the Board, President, Chief Executive Officer -
Michael J. Catelani CPA, MBA,
Pres, COO, CFO & Corp. Sec. -
Michael J. Catelani,
COO, CFO & Corp. Sec. -
Michael Catelani,
Chief Financial Officer, Chief Operating Officer -
Lewis Titterton,
Lead Independent Director -
John Monahan,
Independent Director -
Emily Gottschalk,
Independent Director -
David Cavalier,
Independent Director -
Arnold Baskies,
Independent Director -
Thomas Schlumpberger,
Executive Vice President -
Dr. Pamela D. Garzone Ph.D.,
Chief Devel. Officer -
John Roop,
Sr. VP of Engineering